title: Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor.
abstract: Hemophilia A and B are caused by deficiencies in coagulation factor VIII (FVIII) and factor IX, respectively, resulting in deficient blood coagulation via the intrinsic pathway. The extrinsic coagulation pathway, mediated by factor VIIa and tissue factor (TF), remains intact but is negatively regulated by tissue factor pathway inhibitor (TFPI), which inhibits both factor VIIa and its product, factor Xa. This inhibition limits clot initiation via the extrinsic pathway, whereas factor deficiency in hemophilia limits clot propagation via the intrinsic pathway. ARC19499 is an aptamer that inhibits TFPI, thereby enabling clot initiation and propagation via the extrinsic pathway. The core aptamer binds tightly and specifically to TFPI. ARC19499 blocks TFPI inhibition of both factor Xa and the TF/factor VIIa complex. ARC19499 corrects thrombin generation in hemophilia A and B plasma and restores clotting in FVIII-neutralized whole blood. In the present study, using a monkey model of hemophilia, FVIII neutralization resulted in prolonged clotting times as measured by thromboelastography and prolonged saphenous-vein bleeding times, which are consistent with FVIII deficiency. ARC19499 restored thromboelastography clotting times to baseline levels and corrected bleeding times. These results demonstrate that ARC19499 inhibition of TFPI may be an effective alternative to current treatments of bleeding associated with hemophilia.
authors.affiliation: Archemix Corp., Cambridge, MA, USA.
authors.forename: Emily K
authors.initials: EK
authors.lastname: Waters
authors.forename: Ryan M
authors.initials: RM
authors.lastname: Genga
authors.forename: Michael C
authors.initials: MC
authors.lastname: Schwartz
authors.forename: Jennifer A
authors.initials: JA
authors.lastname: Nelson
authors.forename: Robert G
authors.initials: RG
authors.lastname: Schaub
authors.forename: Karen A
authors.initials: KA
authors.lastname: Olson
authors.forename: Jeffrey C
authors.initials: JC
authors.lastname: Kurz
authors.forename: Kathleen E
authors.initials: KE
authors.lastname: McGinness
mesh_terms: D000818:Animals; D052157:Aptamers, Nucleotide / Q000737:chemistry / Q000494:pharmacology*; D001760:Bleeding Time; D001777:Blood Coagulation / Q000187:drug effects*; D004195:Disease Models, Animal; D005169:Factor VIII / Q000378:metabolism; D015942:Factor VIIa / Q000378:metabolism; D015951:Factor Xa / Q000378:metabolism; D006467:Hemophilia A / Q000097:blood / Q000188:drug therapy; D002836:Hemophilia B / Q000097:blood / Q000188:drug therapy; D006487:Hemostasis / Q000187:drug effects*; D006801:Humans; D066298:In Vitro Techniques; D008074:Lipoproteins / Q000037:antagonists & inhibitors*; D008252:Macaca fascicularis; D011994:Recombinant Proteins / Q000037:antagonists & inhibitors; D013917:Thrombin / Q000096:biosynthesis; D013925:Thromboplastin / Q000378:metabolism
chemical_list: C577143:ARC19499; D052157:Aptamers, Nucleotide; D008074:Lipoproteins; D011994:Recombinant Proteins; C051928:lipoprotein-associated coagulation inhibitor; D005169:Factor VIII; D013925:Thromboplastin; D015942:Factor VIIa; D013917:Thrombin; D015951:Factor Xa